Search

Your search keyword '"Fernandez-Rodriguez, Conrado"' showing total 112 results

Search Constraints

Start Over You searched for: Author "Fernandez-Rodriguez, Conrado" Remove constraint Author: "Fernandez-Rodriguez, Conrado"
112 results on '"Fernandez-Rodriguez, Conrado"'

Search Results

2. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis

3. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure

5. AEEH "Consensus about detection and referral of hidden prevalent liver diseases"

6. Consenso AEEH «Consenso sobre métodos de detección y derivación de enfermedades hepáticas prevalentes ocultas»

7. Development and validation of a scoring system to predict response to obeticholic acid in primary biliary cholangitis.

8. Coordinated assistance plan for the elimination of hepatitis C virus at the centro de ayuda integral al drogodependiente (CAID (Comprehensive Care Centre for Drug Addicts))

10. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

11. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

12. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

13. Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH

14. Enfermedad hepática por alcohol. Guías de práctica clínica. Documento de consenso auspiciado por la AEEH

15. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)

16. Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del Hígado (AEEH)

17. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs

18. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline

19. Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica

22. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication

23. Long-term prospective follow-up of a primary biliary cholangitis (PBC) multicenter cohort treated with Obeticholic Acid (OCA). Interaction effect of triple therapy with fibrates

24. Hepatitis C seroprevalence in an at-risk population in the southwest Madrid region of Spain

25. Seroprevalencia de hepatitis C en población con factores de riesgo del suroeste de la Comunidad de Madrid

27. Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply.

28. Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency-associated hypertransaminasemia

30. Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study

31. Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset

32. Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset

33. ACOX2 deficiency-induced liver fragility (ADILF), a not-so-rare inborn error in bile acid metabolism that responds to ursodeoxycholic acid treatment

34. Beneficial effect of ursodeoxycholic acid in patients with acyl‐CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia

35. TOP-512-YI Metformin as a protective factor against hepatocellular carcinoma in chronic hepatitis C patients achieving sustained virologic response: a long-term follow-up study

36. THU-118 Prophylaxis for tuberculosis and pneumocystis jirovecii does not seem necessary in patients with autoimmune hepatitis treated with corticosteroid therapy: spanish multicentre study

37. THU-155 Incidence of fungal and other opportunistic infections in patients with autoimmune hepatitis: a spanish multicentre study

38. SAT-267 The interaction between metabolic syndrome and alcohol consumption after an episode of alcohol-associated hepatitis is associated with increased mortality: results from de spanish registry of alcohol-associated liver disease (REHALC)

39. SAT-257 Hepatorenal syndrome markedly impacts prognosis of patients with alcohol-associated hepatitis. Results from the spanish registry of alcohol-associated liver disease (REHALC)

42. Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes

44. Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes.

45. WED-270 - Risk of decompensated cirrhosis in patients with primary biliary cholangitis under first, second and third-line therapies

46. TOP-061 - Long-term prospective follow-up of a primary biliary cholangitis (PBC) multicenter cohort treated with Obeticholic Acid (OCA). Interaction effect of triple therapy with fibrates

47. FRI-445 - Recompensation following an episode of alcohol-associated hepatitis mostly occurs in the first year of follow-up and is related to Child-Pugh score, levels of GGT and platelets, and alcohol abstinence

49. Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B

50. Comparative effects of second-line therapy with obeticholic acid or fibrates in primary biliary cholangitis patients

Catalog

Books, media, physical & digital resources